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Background: Coronary artery disease (CAD) is one of the most common diseases leading to mortality and
morbidity worldwide. There is considerable debate on whether serum transforming growth factor β1 (TGF-β1)
levels are associated with long-term major adverse cardiovascular events in patients with CAD, and to date, no
study has specifically addressed levels in patients with different degrees of CAD severity.
Methods: Serum TGF-β1 and mothers against decapentaplegic homolog 3 (SMAD3) concentrations were evaluated
in 279 patients with CAD and 268 controls without CAD. The clinical and biochemical characteristics of all subjects
were also determined and analyzed.
Results: TGF-β1 and SMAD3 concentrations in CAD patients were significantly higher than those in the controls.
The serum TGF-β1 level in acute myocardial infarction (AMI) was significantly higher than that in both stable angina
pectoris (SAP) and unstable angina pectoris (UAP) (p < 0.05), while there was no marked difference between levels
in SAP and UAP (p > 0.05). SMAD3 levels showed no obvious difference among AMI, SAP, and UAP. TGF-β1
and SMAD3 are potential biomarkers for CAD, and may be more accurate than Lpa, ApoA1, uric acid, BUN, or
triglycerides (TG).
Conclusions: Serum TGF-β1 and SMAD3 levels are closely associated with CAD, and may become useful biomarkers
for diagnosis and risk stratification.
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Coronary artery disease (CAD) is one of the leading
causes of mortality and morbidity worldwide, especially
in many developed countries [1,2]. According to the
World Health Organization, it is predicted that 23.6
million deaths per year will be because of cardiovascu-
lar diseases by 2030 [3]. CAD, with a complex etiology,
is considered to be the result of an interaction between
genetic and environmental factors [4-6]. In the past
decades, many contributing factors including smoking,
hypertension, diabetes mellitus (DM), atherosclerosis,
obesity, and diet have been established, but the exact
etiology underlying CAD remains obscure. Increasing* Correspondence: huangcongxin@vip.163.com
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unless otherwise stated.evidence suggests that inflammation plays an important
role in the pathogenesis of CAD [7,8].
A number of inflammatory cytokines mediate adverse
cardiovascular events in patients with CAD, and trans-
forming growth factor-β1 (TGF-β1) has garnered par-
ticular attention because of its multiple roles in important
pathological changes such as enhancement of macrophage
and fibroblast chemotaxis, stimulation of extracellular
matrix (ECM) synthesis, and vascular cell proliferation ab-
normalities [9,10]. Although it has been known that TGF-
β1 activates several pathways, including the extracellular-
regulated kinase pathway, the nuclear factor-κB pathway,
and the phosphatidylinositol-3-kinase pathway [11,12], its
main signaling mechanism is linked to the mothers
against decapentaplegic homolog 3 (SMAD3) family [13].
TGF-β1 binds to its type I receptors and forms a hetero-
meric complex with the type II receptor, which subse-
quently results in phosphorylation and activation of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and biochemical characteristics of the
study population
Variables CAD Control p
Sex (M/F) 168/111 180/88 0.0913
Age (years) 69.30 ± 0.7049 63.73 ±0.6952 < 0.0001
BMI (kg/m2) 23.18 ±0.1337 21.04 ±0.08991 <0.0001
Smoke (%) 12.19 5.60 0.007
Hypertension (%) 26.16 18.66 0.0355
DM (%) 25.81 15.30 0.0024
AF (%) 8.60 0 < 0.0001
Stroke (%) 7.17 1.12 0.0004
High TC (%) 10.39 8.21 0.3796
High TG (%) 13.62 7.09 0.0125
Low HDL (%) 28.32 38.06 0.0155
High LDL (%) 10.04 9.33 0.7798
Lp(a) (mg/l) 265.4 ± 12.43 215.9 ± 11.11 0.0033
BUN (mmol/l) 5.898 ± 0.1978 5.075 ± 0.1675 0.0016
SUA (μmol/l) 340.6 ± 6.018 280.6 ± 6.629 < 0.0001
Glu (mmol/l) 6.549 ± 0.1418 6.011 ± 0.1231 0.0046
CHOL (mmol/l) 4.785 ± 0.07130 4.821 ± 0.2581 0.8885
TG (mmol/l) 1.567 ± 0.07598 1.341 ± 0.04895 0.0148
HDL (mmol/l) 1.256 ± 0.0214 1.242 ±0.02509 0.6613
LDL (mmol/l) 2.854 ± 0.05867 4.190 ± 1.467 0.3377
ApoA1 (g/l) 1.339 ± 0.02123 1.262 ± 0.02484 0.0187
ApoB (g/l) 0.9414 ± 0.01682 0.8810 ± 0.01690 0.0117
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SMAD3. Activated SMAD2 or SMAD3 heterodimerizes
with SMAD4 and then introduces the above complex
into the nucleus, where it regulates the expression of
its target gene [14,15]. TGF-β1/SMAD3-dependent
pathways play a pivotal role in mediating different
biological effects of TGF-β1 such as cell proliferation,
immune suppression, and inflammation [12,16-18]. In
the cardiovascular system, myocardial TGF-β1 ex-
pression is markedly activated in patients with hyper-
trophic or dilated cardiomyopathy, and in experimental
models of myocardial hypertrophy and myocardial in-
farction [19]. Other studies suggest that TGF-β signal-
ing may be crucial for repression of inflammatory gene
expression in healing infarcts mediated by an inflam-
matory infiltrate [20]. TGF-β1 is crucial in the patho-
genesis of infarct healing, cardiac remodeling, and
interstitial fibrosis. There have been few clinical inves-
tigations of TGF-β1/SMAD3 signals in large patient
groups. There is considerable debate over any correl-
ation of TGF-β1 levels with major adverse cardiovas-
cular events in patients with CAD. In particular, no
study has specifically addressed patients with different
degrees of CAD [9].
We collected serum samples from 279 patients with
CAD and from 297 controls, and assessed for any asso-
ciation between serum TGF-β1/SMAD3 levels and the
presence and severity of CAD. We evaluated the poten-
tial clinical application of measurements of these cyto-
kines for CAD diagnosis, comparing their utility with
the currently used biochemical indicators.
Methods
Study population
Written informed consent was obtained from the popu-
lation involved in this study and the study protocol was
approved by the Ethics Committee of Affiliated Hospital
of Guangdong Medical College.
A total of 279 patients who were referred for coronary
angiography by their attending physicians from May to
August 2013, and who were found to have at least 50%
stenosis in at least one coronary artery, were included.
Their ages were about 69.30 years. The 268 controls
were consecutive subjects undergoing routine medical
examinations at the Physical Examination Center. Those
who had any clinical manifestations or a medical history
of heart disorders, a family history of coronary artery
disease, or abnormal ECG were excluded. Exclusion cri-
teria also included acute or chronic infections or inflam-
matory diseases, severe hepatic or renal dysfunction,
malignant tumors, or hematologic disorders. The CAD
group was divided into three subgroups: acute myocar-
dial infarction (AMI), unstable angina pectoris (UAP),
and stable angina pectoris (SAP).Physiological evaluation and blood collection
All study participants underwent a standard clinical
examination. Body mass index (BMI) was calculated as
the individual's body mass divided by the square of their
height. Smoking was defined as having smoked for at
least 1 year currently. Hypertension was defined as a sys-
tolic blood pressure of ≥ 140 mm Hg or use of antihyper-
tensive therapy. Diabetes was diagnosed according to
nonfasting glucose levels ≥ 11.1 mmol/L.
Approximately 2 mL of venous blood was collected
from each subject, and then kept in tubes without
preservatives at 4°C overnight. Serum aliquots were
obtained after centrifugation at 1000 g for 40 min at
4°C.Coronary angiography
All coronary angiographies were performed using stand-
ard technique. Significant CAD was considered to be
present if there was an internal luminal stenosis ≥
50% in the left main coronary artery, right coronary
artery, and/or their major branches. The degree of
coronary atherosclerosis was further categorized accord-
ing to the number of coronary vessels with significant
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and imaging analyses were performed by two experienced
interventional cardiologists who were unaware of the
patients’ clinical data.Biochemical assay
Fasting blood samples were obtained and prepared for
the biochemical assay of clinical indices associated with
CAD diagnosis, including lipoprotein (a) (Lp(a)), blood
urea nitrogen (BUN), uric acid (SUA), blood glucose
(Glu), total cholesterol (CHOL), high-density lipoprotein
(HDL), low-density lipoprotein (LDL), triglycerides (TG),
apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB).Measurements of TGF-β1 and Smad3 levels
Determination of serum active TGF-β1 and SMAD3
concentration was performed by ELISA using the
ELISA-Quantikine kit (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instruc-
tions. The detection range of the ELISA used to meas-
ure TGF-β1 was 100–1200 ng/L, and the detectionTable 2 Clinical and biochemical characteristics of the study p
Variables CAD
AMI SAP
Sex (M/F) 30/21 92/69(M/F)
Age (years) 67.86 ±1.823 69.97 ±0.89
BMI (kg/m2) 22.72 ± 0.2705 23.08 ± 0.1
Smokers (%) 15.69 11.18
Hypertension (%) 31.37 21.12
DM (%) 27.45 27.33
AF (%) 13.72 3.73#
Stroke (%) 7.84 5.59
High TC (%) 19.61 8.07
High TG (%) 17.68 11.80
Low HDL (%) 15.69 30.43
High LDL (%) 13.72 9.32
Lp(a) (mg/l) 292.5 ± 33.46 244.4 ± 14.
BUN (mmol/l) 6.424 ± 0.5315 5.628 ± 0.2
SUA (μmol/l) 364.4 ± 11.62 328.2 ± 8.3
Glu (mmol/l) 6.555 ± 0.3058 6.658 ± 0.1
CHOL (mmol/l) 5.190 ± 0.1761 4.695 ± 0.0
TG (mmol/l) 1.624 ± 0.1808 1.528 ± 0.1
HDL (mmol/l) 1.322 ± 0.04794 1.240 ± 0.0
LDL (mmol/l) 3.134 ± 0.1226 2.798 ± 0.0
ApoA1 (g/l) 1.449 ± 0.05356 1.308 ± 0.0
ApoB (g/l) 1.003 ± 0.04239 0.9385 ± 0.
Date are means ± SEM or n (%).
#p < 0.05 vs SAP or UAP and *p < 0.05, **p < 0.01, ***p < 0.001 vs Control.limit of SMAD3 was 2.5–30 pg/mL. Their accuracy
was expressed in the correlation coefficient, which was
required to be greater than 0.9999.Statistical analysis
Categorical and continuous variables were expressed as
percentiles and mean ± standard error of mean (SEM),
respectively. Differences among groups were assessed
using the chi-squared or analysis of variance tests,
followed by post-hoc analysis (Bonferroni’s correction)
for comparison among groups. The association between
serum TGF-β1 or SMAD3 and CAD or its risk factors
was estimated using a multivariate logistic regression
model.Results
Patient characteristics
The main demographic and clinical characteristics of all
the studied subjects are summarized in Table 1.
There were significant differences between CAD and
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Figure 1 Serum TGF-β1 and SMAD3 levels from CAD patients, ***p < 0.0001, *p < 0.05.
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stroke, TG, HDL, Lp(a), BUN, uric acid, ApoA1, and
ApoB. CAD patients were divided into three subgroups
by pathological types: AMI, SAP, and UAP (Table 2).
The statistical analysis revealed that the risk factors of
CAD mentioned above were significantly higher than in
the controls, and, additionally, several indices, including
BMI, AF, uric acid, total cholesterol, and ApoA1 showed
significant differences among the three subgroups. Dif-
ferent levels of total cholesterol were found in acute
myocardial infarction and angina pectoris patients, but
not in CAD and control subjects.Figure 2 Serum TGF-β1 and SMAD3 levels from patients with differenTGF-β1 and SMAD3 levels in CAD patients
TGF-β1 and SMAD3 levels were both increased signifi-
cantly in the CAD group compared with the controls
(p < 0.0001) (Figure 1). Serum TGF-β1 and SMAD3
levels in the AMI, SAP, and UAP subgroups were all
higher than in the control group (p < 0.0001) (Figure 1),
suggesting that the two cytokines were related to CAD
pathogenesis.
Comparing among the three subgroups of CAD sub-
jects, serum TGF-β1 levels in AMI were significantly
higher than those in both SAP and UAP (p < 0.05), while
there was no marked difference between those in SAPt CAD severity, ***p < 0.0001, *p < 0.05.
Figure 3 Correlation of TGF-β1 or SMAD3 with the risk
factors of CAD, (A) Correlation analysis of TGB- β 1 with
LPa; (B) Correlation analysis of TGB- β with SUA; (C) SMAD3
with Glu. ***p < 0.0001, *p < 0.05.
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were not significantly different among AMI, SAP, and
UAP subgroups, suggesting that TGF-β1 may regulate
the progression from angina pectoris to AMI.
Correlation of TGF-β1 and SMAD3 levels with CAD
occurrence and its risk factors
To explain a potential mechanism of TGF-β1 and
SMAD3, we evaluated their relationship with CAD and
its risk factors including Lp(a), BUN, creatinine, uric
acid, blood glucose, total cholesterol, TG, HDL, LDL,
ApoA1, and ApoB. There was a very significant correl-
ation between CAD and concentration of TGF-β1 and
SMAD3 (p < 0.0001). Among the other biochemical indices
[21], TGF-β1 significantly correlated with Lp(a) (p < 0.0203)
and uric acid (p < 0.0001), respectively, and SMAD3 corre-
lated very significantly with blood glucose (p < 0.0001)
(Figure 3).
TGF-β1 and SMAD3 as biomarkers for CAD
Far higher TGF-β1 and SMAD3 concentrations occurred
in CAD patients (TGF-β1: 432.2 ± 22.12 ng/L; SMAD3:
11.47 ± 0.6161 ng/L) compared with controls (TGF-β1:
220.1 ± 8.831 ng/L; SMAD3: 5.157 ± 0.1965 ng/L). The
area under the Receiver operating characteristic curves
(AUCROC) indicated that both TGF-β1 (AUCROC: 0.678,
95% confidence interval [CI]: 0.633–0.723) and SMAD3
(AUCROC: 0.715, 95% CI: 0.672–0.758) were the more
potent biomarkers for CAD, compared with Lpa (AUCROC:
0.574, 95% CI: 0.525–0.623), ApoA1 (AUCROC: 0.561, 95%
CI: 0.512–0.609), uric acid (AUCROC: 0.663, 95% CI:
0.617–0.710), BUN (AUCROC: 0.581, 95% CI: 0.533–0.630),
or TG (AUCROC: 0.545, 95% CI: 0.496–0.594) (Figure 4).
Discussion
TGF-β1 is a multifunctional peptide that controls prolif-
eration, differentiation, and other functions in many cell
types, and it has dual regulation roles in immune re-
sponse and cellular development. TGF-β1 acts synergis-
tically with TGFα in inducing transformation. It also
acts as a negative autocrine growth factor. Dysregulation
of TGF-β1 activation and signaling may result in apop-
tosis. For example, TGF-β1 inhibits cancer cell growth at
the early stage of tumor formation, and promotes the
cancer development in the late phase [22].
Previous studies have shown plasma TGF-β1 levels to
be reduced in patients with advanced atherosclerosis
and angiographically proven CAD. The levels of TGF-β1
were thought to be inversely related to the development
and severity of coronary disease [23-27]. By contrast,
Border and Ruoslahti found that TGF-β1 could enhance
atherogenesis by mediating excessive ECM deposition
[28]. Another recent study revealed that a high plasma
level of TGF-β had a significantly strong prognosis interms of survival without cardiovascular events and sur-
vival without coronary interventions compared with the
low TGF-β group (both p < 0.05), suggesting that plasma
TGF-β may potentially have great prognostic value in
patients with CAD [29]. Schaan et al maintained that
serum TGF-β1 was not associated with CAD occurrence
after clinical and laboratory evaluation of TGF-β1 in pa-
tients with CAD or DM [9]. However, they sampled
Figure 4 Receiver operating characteristic (ROC) curves for TGF-β1 and SMAD3. The area under the curve of TGF-β1 was 0.678 (95% confi-
dence interval [CI], 0.633–0.723). The area under the curve of SMAD3 was 0.715 (95% CI, 0.672–0.758).
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tive correlation between serum TGF-β1/SMAD3 levels
and CAD based on 547 subjects.
There has been no study stratifying patients according
to CAD severity. It is probable that the relevance of
TGF-β1 in CAD can only be detected in severe disease,
or high concentrations of TGF-β1 from severe CAD
may have a paradoxical effect [27,30,31].
In the correlation of TGF-β1 and SMAD3 levels with
the risk factors of CAD, TGF-β1 is closely related to Lp
(a) and uric acid, which both are considered to be
markers of atherosclerosis, indicating that this cytokine
may contribute to the establishment of CAD by regulat-
ing atherogenesis. SMAD3 levels correlated closely with
blood glucose, implying that SMAD3 may influence
CAD occurrence and the development of DM. Interest-
ingly, it has been reported that risk factors including Lp
(a), uric acid, BUN, triglycerides, and ApoA1 can be use-
ful biomarkers for different clinical diagnoses [21,32],
but we found that TGF-β1 and SMAD3 were more sen-
sitive biomarkers for CAD than those factors mentioned
above.
Conclusion
Serum TGF-β1 and SMAD3 levels are closely associated
with CAD. The underlying mechanism may be their
regulatory effects on atherosclerosis and blood sugar.A limitation of the present study is that the control
population differs from the cases, in terms of age and
cardiovascular risk factors. The mean age difference
(~5 years) should be acceptable in an epidemiologic
study of CAD according to a previous report [6,9]. CAD
predominates in an older population.
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